Several in vivo biomarkers of neurofibrillary tangle development include PET and soluble phosphorylated tau (p-tau) levels in human cerebrospinal fluid (CSF), and more recently p-tau in blood plasma [16]. The gene discussed is MAPT; the disease is Neurofibrillary tangles.